(Q59652471)

English

Efficacy and safety of alirocumab, a fully human PCSK9 monoclonal antibody, in high cardiovascular risk patients with poorly controlled hypercholesterolemia on maximally tolerated doses of statins: rationale and design of the ODYSSEY COMBO I and II t

article

In more languages

Statements

scholarly article

0 references

Efficacy and safety of alirocumab, a fully human PCSK9 monoclonal antibody, in high cardiovascular risk patients with poorly controlled hypercholesterolemia on maximally tolerated doses of statins: rationale and design of the ODYSSEY COMBO I and II t (English)

0 references

monoclonal antibody

1 reference

based on heuristic

inferred from title

object named as

Dirk Blom

5

0 references

Helen M. Colhoun

object named as

Helen M Colhoun

1

0 references

Dean J Kereiakes

6

object named as

Dean J Kereiakes

0 references

author name string

Jennifer G Robinson

2

0 references

Michel Farnier

3

0 references

Bertrand Cariou

4

0 references

Christelle Lorenzato

7

0 references

Robert Pordy

8

0 references

Umesh Chaudhari

9

0 references

language of work or name

0 references

publication date

20 September 2014

0 references

BMC Cardiovascular Disorders

0 references

14

0 references

1

0 references

121

0 references

https://scigraph.springernature.com/pub.10.1186/1471-2261-14-121

0 references

MMRM vs. LOCF: a comprehensive comparison based on simulation study and 25 NDA datasets

1 reference

https://pubmed.ncbi.nlm.nih.gov/25240705

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Safety and efficacy of a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 serine protease, SAR236553/REGN727, in patients with primary hypercholesterolemia receiving ongoing stable atorvastatin therapy

1 reference

https://pubmed.ncbi.nlm.nih.gov/25240705

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Atorvastatin with or without an antibody to PCSK9 in primary hypercholesterolemia

1 reference

https://pubmed.ncbi.nlm.nih.gov/25240705

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Use of Lipid-Lowering Medications and the Likelihood of Achieving Optimal LDL-Cholesterol Goals in Coronary Artery Disease Patients

1 reference

https://pubmed.ncbi.nlm.nih.gov/25240705

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Clinical aspects of PCSK9.

1 reference

https://pubmed.ncbi.nlm.nih.gov/25240705

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Effect of a monoclonal antibody to PCSK9, REGN727/SAR236553, to reduce low-density lipoprotein cholesterol in patients with heterozygous familial hypercholesterolaemia on stable statin dose with or without ezetimibe therapy: a phase 2 randomised con

1 reference

https://pubmed.ncbi.nlm.nih.gov/25240705

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy

1 reference

https://pubmed.ncbi.nlm.nih.gov/25240705

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

First-line treatment patterns and lipid target levels attainment in very high cardiovascular risk outpatients

1 reference

https://pubmed.ncbi.nlm.nih.gov/25240705

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

2012 update of the Canadian Cardiovascular Society guidelines for the diagnosis and treatment of dyslipidemia for the prevention of cardiovascular disease in the adult

1 reference

https://pubmed.ncbi.nlm.nih.gov/25240705

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

ESC/EAS Guidelines for the management of dyslipidaemias: the Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS).

1 reference

https://pubmed.ncbi.nlm.nih.gov/25240705

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Centralized Pan-European survey on the under-treatment of hypercholesterolaemia (CEPHEUS): overall findings from eight countries

1 reference

https://pubmed.ncbi.nlm.nih.gov/25240705

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Lipid-altering efficacy of ezetimibe plus statin and statin monotherapy and identification of factors associated with treatment response: a pooled analysis of over 21,000 subjects from 27 clinical trials.

1 reference

https://pubmed.ncbi.nlm.nih.gov/25240705

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

High-dose atorvastatin causes a rapid sustained increase in human serum PCSK9 and disrupts its correlation with LDL cholesterol

1 reference

https://pubmed.ncbi.nlm.nih.gov/25240705

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials

1 reference

https://pubmed.ncbi.nlm.nih.gov/25240705

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Blood cholesterol and vascular mortality by age, sex, and blood pressure: a meta-analysis of individual data from 61 prospective studies with 55,000 vascular deaths

1 reference

https://pubmed.ncbi.nlm.nih.gov/25240705

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Effect of alirocumab, a monoclonal antibody to PCSK9, on long-term cardiovascular outcomes following acute coronary syndromes: rationale and design of the ODYSSEY outcomes trial

1 reference

https://pubmed.ncbi.nlm.nih.gov/25240705

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Intermittent nondaily dosing strategies in patients with previous statin-induced myopathy.

1 reference

https://pubmed.ncbi.nlm.nih.gov/25240705

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Executive summary: heart disease and stroke statistics--2013 update: a report from the American Heart Association

1 reference

https://pubmed.ncbi.nlm.nih.gov/25240705

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Are the ACC/AHA Guidelines on the Treatment of Blood Cholesterol a Game Changer? A Perspective From the Canadian Cardiovascular Society Dyslipidemia Panel

1 reference

https://pubmed.ncbi.nlm.nih.gov/25240705

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Prevalence and overlap of different lipid abnormalities in statin-treated patients at high cardiovascular risk in clinical practice in Germany

1 reference

https://pubmed.ncbi.nlm.nih.gov/25240705

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Effects of combination lipid therapy in type 2 diabetes mellitus

1 reference

https://pubmed.ncbi.nlm.nih.gov/25240705

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Prevalence of dyslipidemia and lipid goal attainment in statin-treated subjects from 3 data sources: a retrospective analysis

1 reference

https://pubmed.ncbi.nlm.nih.gov/25240705

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Determinants of low-density lipoprotein cholesterol goal attainment: Insights from the CEPHEUS Pan-Asian Survey

1 reference

https://pubmed.ncbi.nlm.nih.gov/25240705

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines

1 reference

https://pubmed.ncbi.nlm.nih.gov/25240705

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

European Guidelines on cardiovascular disease prevention in clinical practice (version 2012). The Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted

1 reference

https://pubmed.ncbi.nlm.nih.gov/25240705

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Cardiovascular prevention guidelines in daily practice: a comparison of EUROASPIRE I, II, and III surveys in eight European countries

1 reference

https://pubmed.ncbi.nlm.nih.gov/25240705

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines

1 reference

https://pubmed.ncbi.nlm.nih.gov/25240705

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Serum cholesterol levels and six-year mortality from stroke in 350,977 men screened for the multiple risk factor intervention trial

1 reference

https://pubmed.ncbi.nlm.nih.gov/25240705

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta-analysis of individual data from 27 randomised trials

1 reference

https://pubmed.ncbi.nlm.nih.gov/25240705

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The secretory proprotein convertase neural apoptosis-regulated convertase 1 (NARC-1): liver regeneration and neuronal differentiation

1 reference

https://pubmed.ncbi.nlm.nih.gov/25240705

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Achievement of treatment goals for primary prevention of cardiovascular disease in clinical practice across Europe: the EURIKA study

1 reference

https://pubmed.ncbi.nlm.nih.gov/25240705

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Low LDL cholesterol, statins, and brain hemorrhage: should we worry?

1 reference

https://pubmed.ncbi.nlm.nih.gov/25240705

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Adherence with statin therapy in elderly patients with and without acute coronary syndromes

1 reference

https://pubmed.ncbi.nlm.nih.gov/25240705

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Intensive lowering of LDL cholesterol with 80 mg versus 20 mg simvastatin daily in 12,064 survivors of myocardial infarction: a double-blind randomised trial

1 reference

https://pubmed.ncbi.nlm.nih.gov/25240705

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Treating statin-intolerant patients

1 reference

https://pubmed.ncbi.nlm.nih.gov/25240705

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

PCSK9 inhibitors

1 reference

https://pubmed.ncbi.nlm.nih.gov/25240705

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

A proprotein convertase subtilisin/kexin type 9 neutralizing antibody reduces serum cholesterol in mice and nonhuman primates

1 reference

https://pubmed.ncbi.nlm.nih.gov/25240705

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Therapeutic practice patterns related to statin potency and ezetimibe/simvastatin combination therapies in lowering LDL-C in patients with high-risk cardiovascular disease

1 reference

https://pubmed.ncbi.nlm.nih.gov/25240705

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1186/1471-2261-14-121

0 references

Dimensions Publication ID

0 references

PMC publication ID

0 references

PubMed publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q59652471&oldid=1647976856"